SRX is profitable, pays a divi, reported a 35% increase in sales this Qtr and has an unbroken growth in sales stretching back many years. It currently treats less than 1% of its potential market, and is funding trails to see if its treatment would work for other forms of cancer.
Don’t hold any – but like the prospects of the company.
